Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerlan - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage ...

ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in ...

Sage Therapeutics Inc. has synthesized sterol derivatives acting as glutamate receptor ionotropic, NMDA 2A (GRIN2A; GluN2A) negative allosteric modulators reported to be useful for the treatment of ...

The study also clarifies the functional role of the receptor's conserved sodium-binding pocket, showing that sodium egress strongly promotes activation-related conformational states, including a ...

Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...

Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...

Vanderbilt University has synthesized metabotropic glutamate (mGlu2) receptor negative allosteric modulators reported to be useful for the treatment of depression, anxiety, Alzheimer's disease, autism ...

Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...

ADDEX raises US$ 2.8 million through its At the Market agreement and extends cash runway to the fourth quarter of 2027: Geneva, Switzerland Thursday, August 27, 2026, 18:00 Hrs [I ...